Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company that focuses on the development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases. The company's primary function is to address unmet medical needs by working on advanced treatments targeting conditions that often lack effective therapies. Ultragenyx is primarily involved in the biotechnology sector, impacting areas such as gene therapy, small molecule drugs, and advanced biologic therapies. The company engages in various stages of product development, from clinical trials to commercialization, emphasizing collaboration with academic institutions and other pharmaceutical companies. Its innovative approaches leverage genetic information to develop tailored treatments, aiming to improve patients' quality of life. Ultragenyx’s market significance lies in its specialized focus, contributing to therapeutics that typically see less attention due to smaller patient populations. Founded in 2010 and headquartered in Novato, California, Ultragenyx continues to play a crucial role in the biopharmaceutical industry by pushing boundaries in niche markets and focusing on precision medicine for rare genetic disorders.